Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial

Glucose variability has been associated with cardiovascular outcomes in type 2 diabetes, however, the interplay between glucose variability, empagliflozin and cardiovascular death has not been explored. In the...

Source: Cardiovascular Diabetology - October 13, 2020 Category: Cardiology Authors: Antonio Ceriello, Anne Pernille Ofstad, Isabella Zwiener, Stefan Kaspers, Jyothis George and Antonio Nicolucci Tags: Original investigation Source Type: research